• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 4:17:07 PM ET
    $AGTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGTC alert in real time by email
    SC 13G/A 1 d133830dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Applied Genetic Technologies Corporation

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    03820J100

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing of this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Intersouth Partners VI, L.P.

      2.    

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3.    

      SEC Use Only

     

      4.    

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

      Beneficially  

    Owned By

    Each

    Reporting

    Person

    with

        5.     

      Sole Voting Power

     

      0

      6.     

      Shared Voting Power

     

      1,214,457

      7.     

      Sole Dispositive Power

     

      0

      8.     

      Shared Dispositive Power

     

      1,214,457

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,214,457

    10.    

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.    

      Percent of Class Represented by Amount in Row (9)

     

      4.7%(1)

    12.    

      Type of Reporting Person

     

      PN

     

    1 

    This percentage is calculated based upon 25,889,625 shares of common stock outstanding on November 11, 2020 as reported by Applied Genetic Technologies Corporation (the “Issuer”) on its Form 10-Q for the quarterly period ended September 30, 2020 (the Form 10-Q”) as filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2020.

     

    2


      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Intersouth Associates VI, LLC

      2.    

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3.    

      SEC Use Only

     

      4.    

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

      Beneficially  

    Owned By

    Each

    Reporting

    Person

    with

        5.     

      Sole Voting Power

     

      0

      6.     

      Shared Voting Power

     

      1,214,457

      7.     

      Sole Dispositive Power

     

      0

      8.     

      Shared Dispositive Power

     

      1,214,457

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,214,457

    10.    

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.    

      Percent of Class Represented by Amount in Row (9)

     

      4.7%(2)

    12.    

      Type of Reporting Person

     

      00

     

     

    2 

    This percentage is calculated based upon 25,889,625 shares of common stock outstanding on November 11, 2020 as reported by the Issuer on its Form 10-Q as filed with the SEC on November 16, 2020.

     

    3


      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Dennis Dougherty

      2.    

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3.    

      SEC Use Only

     

      4.    

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

      Beneficially  

    Owned By

    Each

    Reporting

    Person

    with

        5.     

      Sole Voting Power

     

      0

      6.     

      Shared Voting Power

     

      1,214,457

      7.     

      Sole Dispositive Power

     

      0

      8.     

      Shared Dispositive Power

     

      1,214,457

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,214,457

    10.    

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.    

      Percent of Class Represented by Amount in Row (9)

     

      4.7%(3)

    12.    

      Type of Reporting Person

     

      IN

     

     

    3 

    This percentage is calculated based upon 25,889,625 shares of common stock outstanding on November 11, 2020 as reported by the Issuer on its Form 10-Q as filed with the SEC on November 16, 2020.

     

    4


      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Mitch Mumma

      2.    

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3.    

      SEC Use Only

     

      4.    

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

      Beneficially  

    Owned By

    Each

    Reporting

    Person

    with

        5.     

      Sole Voting Power

     

      0

      6.     

      Shared Voting Power

     

      1,214,457

      7.     

      Sole Dispositive Power

     

      0

      8.     

      Shared Dispositive Power

     

      1,214,457

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,214,457

    10.    

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.    

      Percent of Class Represented by Amount in Row (9)

     

      4.7%(4)

    12.    

      Type of Reporting Person

     

      IN

     

     

    4 

    This percentage is calculated based upon 25,889,625 shares of common stock outstanding on November 11, 2020 as reported by the Issuer on its Form 10-Q as filed with the SEC on November 16, 2020.

     

    5


    Item 1(a)

    Name of Issuer

    Applied Genetic Technologies Corporation (the “Issuer”)

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices

    11801 Research Drive, Suite D

    Alachua, Florida 32615

     

    Item 2(a)

    Name of Persons Filing

    Intersouth Partners VI, L.P. (“ISP VI”)

    Intersouth Associates VI, LLC (“ISA VI, LLC”)

    Dennis Dougherty

    Mitch Mumma (together with ISP VI, ISA VI, LLC, and Mr. Dougherty, the “Reporting Persons”).

     

    Item 2(b)

    Address of Principal Business Office, or if none, Residence

    For each of the Reporting Persons:

    c/o Intersouth Partners

    4711 Hope Valley Road

    Suite 4F - 632

    Durham, North Carolina 27707

     

    Item 2(c)

    Citizenship

    ISP VI – Delaware limited partnership

    ISA VI, LLC – Delaware limited liability company

    Dennis Dougherty – United States of America

    Mitch Mumma – United States of America

     

    Item 2(d)

    Title of Class of Securities

    Common Stock, $0.001 par value per share

     

    Item 2(e)

    CUSIP Number

    03820J100

     

    Item 3.

    Filing pursuant to Rules 13d-1(b) or 13d-2(b) or (c)

    Not Applicable

     

    Item 4.

    Ownership

     

      (a)

    Amount Beneficially Owned

     

    6


    The Reporting Persons are the owners of an aggregate of 1,214,457 shares of Common Stock, which represents 4.7% of the Issuer’s outstanding common stock based upon 25,889,625 shares of common stock outstanding on November 11, 2020 as reported on its form 10-Q as filed with the SEC on November 16, 2020. ISP VI directly beneficially owns 1,214,457 shares of Common Stock, or 4.7% of the Issuer’s common stock outstanding. ISA VI, LLC, as the general partner of ISP VI, may be deemed to indirectly beneficially own the securities owned by ISP VI. Messrs. Dougherty and Mumma, as Member Managers of ISA VI, LLC, may be deemed to indirectly beneficially own the securities owned by ISP VI.

    Each of (i) ISP VI, (ii) ISA VI, LLC, and (iii) Messrs. Dougherty and Mumma, may be deemed to share the power to vote or direct the voting of, and to dispose or direct the disposition of, the securities of Issuer that are directly beneficially owned by ISP VI. Each of Messrs. Dougherty and Mumma disclaims beneficial ownership of all securities other than those he owns by virtue of his indirect pro rata interest as a member of ISA VI, LLC.

     

      (b)

    Percent of Class

    ISP VI – 4.7%

    ISA VI, LLC – 4.7%

    Mitch Mumma – 4.7%

    Dennis Dougherty – 4.7%

    The above percentages are based on 25,889,625 shares of common stock outstanding on November 11, 2020 as reported on its form 10-Q as filed with the SEC on November 16, 2020.

     

      (c)

    Number of shares as to which the person has;

     

      (i)

    sole power to vote or direct the vote:

    ISP VI – 0

    ISA VI, LLC – 0

    Mitch Mumma – 0

    Dennis Dougherty - 0

     

      (ii)

    shared power to vote or direct the vote:

    ISP VI - 1,214,457

    ISA VI, LLC – 1,214,457

    Mitch Mumma – 1,214,457

    Dennis Dougherty – 1,214,457

    (See Item 4(a))

     

      (iii)

    sole power to dispose or direct the disposition of:

    ISP VI – 0

    ISA VI, LLC – 0

    Mitch Mumma – 0

    Dennis Dougherty - 0

     

    7


      (iv)

    shared power to dispose or direct the disposition of:

    ISP VI - 1,214,457

    ISA VI, LLC – 1,214,457

    Mitch Mumma – 1,214,457

    Dennis Dougherty – 1,214,457

    (See Item 4(a))

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not Applicable

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibit Index

    Exhibit A – Joint Filing Agreement is incorporated by reference to Exhibit A included in the Schedule 13G filed by the Reporting Persons on April 28, 2014.

     

    8


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to such person is true, complete and correct.

    Date:    February 12, 2021

     

    INTERSOUTH PARTNERS VI, L.P.

    By:  

    Intersouth Associates VI, LLC

    its General Partner

    By:  

    /s/ Dennis Dougherty

    Name:   Dennis Dougherty
    Title:   Member Manager
    INTERSOUTH ASSOCIATES VI, L.P.
    By: Intersouth Associates VI, LLC its General Partner
    By:  

    /s/ Mitch Mumma

    Name:   Mitch Mumma
    Title:   Member Manager

    /s/ Dennis Dougherty

    Dennis Dougherty

    /s/ Mitch Mumma

    Mitch Mumma

     

    9

    Get the next $AGTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AGTC
    Financials

    Live finance-specific insights

    See more
    • Syncona to Acquire Applied Genetic Technologies Corporation

      Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC's closing stock price on October 21, 2022 Total consideration of up to $1.07, including up to $0.73 per CVR, representing a premium of up to approximately 344% over AGTC's closing stock price on October 21, 2022 AGTC's Board has examined all alternative options for the future of AGTC and believes this transaction clearly delivers the best value for shareholders Given the state of equity and other funding markets, AGTC sees significant challenges in funding ongoing operations beyond 2022 Syncona and AGTC to host conference call on October 24, 2022 at 7:30 a.m. ET

      10/23/22 10:05:16 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

      – 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study's Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety and Efficacy Data Consistent with Previously Reported Results from the Phase 1/2 Trial in XLRP – – Company to Host Conference Call to Review Data on May 17 at 8:00 a.m. ET – GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited ret

      5/16/22 4:01:00 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021

      -Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced financial results for the quarter ended December 31, 2021. "We enter 2022 with significant momentum from the recent buildout of our management team

      2/14/22 7:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Applied Genetic Technologies Corporation

      15-12G - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

      12/12/22 8:33:58 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Applied Genetic Technologies Corporation

      EFFECT - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

      12/7/22 12:15:06 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Applied Genetic Technologies Corporation

      EFFECT - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

      12/7/22 12:15:13 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AGTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BTIG initiated coverage on Applied Genetic with a new price target

      BTIG initiated coverage of Applied Genetic with a rating of Buy and set a new price target of $11.00

      6/15/21 6:43:59 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stifel Nicolaus initiated coverage on Applied Genetic Technologies with a new price target

      Stifel Nicolaus initiated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $14.00

      3/8/21 8:22:11 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stifel initiated coverage on Applied Genetic Technologies with a new price target

      Stifel initiated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $14.00

      3/2/21 6:25:42 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), announced today the successful completion of the previously announced tender offer (the "Offer") to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) ("Syncona"). The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. Pursuant to the terms of the definitive merger agreement, AGTC stockholders are entitled t

      12/1/22 7:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) ("Syncona") has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones. The tender offer has been extended until 5:00 p.m., Eastern Time, on November 30, 2022. The tender offer was previously scheduled to exp

      11/29/22 8:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • *FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC common stock at a price per share of $0.34 in cash plus the right for AGTC stockholders to receive additional aggregate payments of up to $0.73 per share upon the achievement of specified milestones. We urge you to tender your shares in the offer.In order to tender, please contact your bank or broker, or follow the instructions that you previously received by mail or email from

      11/28/22 8:30:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer

      Leading Ophthalmologist and Experienced Industry Executive to Advance Development of Innovative Corneal Endothelial Cell Therapy Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer. Dr. Goldstein will lead the Company's clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cell therapy to treat corneal edema secondary to endothelial dysfunction. This press release features multimedia. View the full release here: https://www.businesswire.c

      6/9/22 8:00:00 AM ET
      $AGTC
      $OCUL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced the appointment of James Robinson, President and Chief Executive Officer (CEO) of Urovant Sciences, to its Board of Directors. "We are honored to have Jim join our Board of Directors, where his exemplary track record of execution as an executive at leading biotech and pharma companies will b

      12/6/21 8:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer

      With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance AGTC's preclinical pipeline GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the appointment of Abraham Scaria, Ph.D., as Chief Science Officer. "A gene

      11/16/21 8:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Applied Genetic Technologies Corporation (Amendment)

      SC 13G/A - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

      2/14/23 1:22:16 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Applied Genetic Technologies Corporation

      SC 13D - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

      12/8/22 12:42:24 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Applied Genetic Technologies Corporation

      SC 13G - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

      11/4/22 4:24:20 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Robinson James A. Jr.

      4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

      12/1/22 9:23:47 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Vanlent Anne

      4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

      12/1/22 9:23:04 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Rosen James closing all direct ownership in the company (for withholding tax)

      4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

      12/1/22 9:22:27 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care